(Q42776525)

7 November 2017

title

Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients (English)

1 reference

chronic obstructive pulmonary disease

7 November 2017

main subject

1 reference

1 reference

2

1 reference

7 November 2017

author name string

Boudewijn Van de Maele

1

1 reference

7 November 2017

Carmen Martin

3

1 reference

7 November 2017

Rachael Horton

4

1 reference

7 November 2017

Michael Dolker

5

1 reference

7 November 2017

Tim Overend

6

1 reference

7 November 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

COPD: Journal of Chronic Obstructive Pulmonary Disease

7 November 2017

published in

1 reference

7 November 2017

volume

7

1 reference

7 November 2017

issue

6

1 reference

7 November 2017

page(s)

418-427

1 reference

The functional impact of adding salmeterol and tiotropium in patients with stable COPD.

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Safety of long-acting beta-agonists in stable COPD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Cardiovascular safety of salmeterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

Cardiovascular safety of tiotropium in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2010.528812

10.3109/15412555.2010.528812

21 January 2018

Identifiers

DOI

1 reference

7 November 2017

1 reference